Cytosorbents (CTSO) Operating Expenses (2010 - 2026)

Cytosorbents' Operating Expenses history runs 17 years deep, the most recent figure standing at $9.2 million for Q1 2026.

• Quarterly Operating Expenses fell 9.12% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.3 million (up 1.04% YoY) and the FY2025 annual result came in at $41.2 million, changed 0.24% from the prior year.
• Operating Expenses was $9.2 million for Q1 2026 at Cytosorbents, down from $11.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $14.6 million in Q4 2023 and bottomed at $9.2 million in Q1 2026.
• A 5-year average of $11.6 million and a median of $11.5 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 32.76% — and 2024, when it tumbled 34.1%.
• Cytosorbents' Operating Expenses stood at $12.1 million in 2022, then gained by 20.88% to $14.6 million in 2023, then tumbled by 34.1% to $9.6 million in 2024, then climbed by 15.95% to $11.2 million in 2025, then slipped by 18.01% to $9.2 million in 2026.
• Business Quant data shows CTSO's Operating Expenses at $9.2 million in Q1 2026, $11.2 million in Q4 2025, and $9.5 million in Q3 2025.